Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

2期 已完成 NCT04924101

摘要

The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage small cell Lung Cancer (ES-SCLC). No formal hypothesis testing will be performed for this study.

Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

Up to approximately 43 months · Percentage of participants

Six-Month Progression-Free Survival (PFS) Rate as Assessed by BICR Per RECIST 1.1

At 6 months · Percentage of Participants

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given P — Merck Sharp & Dohme LLC
• Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers — Rutgers, The State University of New Jersey
• Evaluation of Advanced Imaging and Visualization for Clinical Deep Brain Stimulation — Duke University
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemot — Merck Sharp & Dohme LLC
• A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advan — Merck Sharp & Dohme LLC
• A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With E — Hoffmann-La Roche

全部试验